March 21, 2008 — Fred Hutchinson Cancer Research Center (FHCRC) and NSB POSTECH Inc. (NSB) have reached an agreement to coordinate their efforts and to determine the efficacy of the NSB’s NanoCones surface technology in creating proteomic microarrays to be used in the study of human diseases.
NSB is a South Korean biotech company that possesses a proprietary microarray technology and expertise in nano-scale controlled surface chemistry. NSB has agreed to fund the collaboration, which will involve a comparison of slides created with NSB’s newly developed NanoCones surface technology and the current industry standard.
“This is the first time a Korean biotech company has had an opportunity to collaborate with a major US-based cancer research center,” says Dr. Joon Won Park, president of NSB and one of the inventors of the NanoCones technology.
At Fred Hutchinson Cancer Research Center, interdisciplinary teams of scientists and humanitarians work together to prevent, diagnose, and treat cancer, HIV/AIDS, and other diseases.